Literature DB >> 15716519

Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer's disease.

P J Connelly1, N P Prentice, K G Fowler.   

Abstract

OBJECTIVE: To investigate the possibility that response to cholinesterase inhibitor therapy could be predicted by easily measurable variables that are known to change as a result of treatment (such as the Mini Mental State Examination), measures of function (such as the instrumental activities of daily living and the social behaviour subscales of the Nurse's Observation Scale for Geriatric Patients), and measures of attention (such as the Digit Symbol Substitution Test; DSST), or that might influence response through structural (for example, age, cerebrovascular disease, medial temporal lobe (MTL) atrophy, hypertension) or chemical (for example, smoking) mechanisms.
METHOD: This was a cohort study of 160 consecutive outpatients with probable Alzheimer's disease who commenced cholinesterase inhibitor treatment over a 3 year period in a semi-rural area of Scotland.
RESULTS: The overall response rate was 42.1%. Stratification of response between good and poor responders was possible using baseline DSST and a measure of MTL thickness using CT. Among the patients, 60.4% of those above the cut off point for both DSST and MTL thickness (29/48 subjects) were classified as good responders, compared with 6.3% of subjects below the cut off point for both (1/16 subjects). Subjects above the cut off point for both measures were more likely to be classified as good responders than subjects with only one or no values above the respective cut off points (chi(2) = 10.61, df = 1, p = 0.001)
CONCLUSIONS: The DSST and a measure of MTL thickness derived from CT scanning may be useful in improving the prediction of response to cholinesterase inhibitors in subjects with AD. Subjects with low DSST scores and more severe MTL atrophy are unlikely to respond to treatment. These preliminary data justify a prospective trial of the usefulness of our suggested predictive measures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15716519      PMCID: PMC1739548          DOI: 10.1136/jnnp.2004.043539

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  37 in total

1.  Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil.

Authors:  M Evans; A Ellis; D Watson; T Chowdhury
Journal:  Int J Geriatr Psychiatry       Date:  2000-01       Impact factor: 3.485

2.  Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computed tomography.

Authors:  K A Jobst; A D Smith; M Szatmari; A Molyneux; M E Esiri; E King; A Smith; A Jaskowski; B McDonald; N Wald
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

3.  White-matter hyperintensity and neuropsychological functions in dementia and healthy aging.

Authors:  O Almkvist; L O Wahlund; G Andersson-Lundman; H Basun; L Bäckman
Journal:  Arch Neurol       Date:  1992-06

4.  A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses' Observation Scale for Geriatric Patients).

Authors:  R Spiegel; C Brunner; D Ermini-Fünfschilling; A Monsch; M Notter; J Puxty; L Tremmel
Journal:  J Am Geriatr Soc       Date:  1991-04       Impact factor: 5.562

5.  Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree.

Authors:  C Villardita; S Grioli; C Lomeo; C Cattaneo; J Parini
Journal:  Neuropsychobiology       Date:  1992       Impact factor: 2.328

6.  Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB.

Authors:  B J Sahakian; A M Owen; N J Morant; S A Eagger; S Boddington; L Crayton; H A Crockford; M Crooks; K Hill; R Levy
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients.

Authors:  K Alhainen; E L Helkala; P Riekkinen
Journal:  Dementia       Date:  1993 Jan-Feb

8.  Periventricular white matter changes and dementia. Clinical, neuropsychological, radiological, and pathological correlation.

Authors:  S R Gupta; M H Naheedy; J C Young; M Ghobrial; F A Rubino; W Hindo
Journal:  Arch Neurol       Date:  1988-06

9.  Pathological verification of ischemic score in differentiation of dementias.

Authors:  W G Rosen; R D Terry; P A Fuld; R Katzman; A Peck
Journal:  Ann Neurol       Date:  1980-05       Impact factor: 10.422

10.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease.

Authors:  J Poirier; M C Delisle; R Quirion; I Aubert; M Farlow; D Lahiri; S Hui; P Bertrand; J Nalbantoglu; B M Gilfix; S Gauthier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

View more
  17 in total

1.  Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease.

Authors:  Kathy Dujardin; David Devos; Stéphane Duhem; Alain Destée; Rose-Marie Marié; Franck Durif; Lucette Lacomblez; Jacques Touchon; Pierre Pollak; Jean-Jacques Péré
Journal:  J Neurol       Date:  2006-09-22       Impact factor: 4.849

Review 2.  Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.

Authors:  Julien Delrieu; Antoine Piau; Céline Caillaud; Thierry Voisin; Bruno Vellas
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

3.  Long-term use of pharmacological treatment in Alzheimer's disease: a retrospective cohort study in real-world clinical practice.

Authors:  G Lombardi; N Lombardi; A Bettiol; G Crescioli; C Ferrari; G Lucidi; C Polito; V Berti; V Bessi; S Bagnoli; B Nacmias; A Vannacci; S Sorbi
Journal:  Eur J Clin Pharmacol       Date:  2022-04-28       Impact factor: 2.953

4.  Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review.

Authors:  Federico Emanuele Pozzi; Elisa Conti; Ildebrando Appollonio; Carlo Ferrarese; Lucio Tremolizzo
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

5.  Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.

Authors:  Marwan Sabbagh; Jeffrey Cummings; Daniel Christensen; Rachelle Doody; Martin Farlow; Liang Liu; Joan Mackell; Randi Fain
Journal:  BMC Geriatr       Date:  2013-06-06       Impact factor: 3.921

6.  The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease.

Authors:  Takashi Ohnishi; Yojiro Sakiyama; Yuichi Okuri; Yuji Kimura; Nami Sugiyama; Takayuki Saito; Masayoshi Takahashi; Takumi Kobayashi
Journal:  Curr Alzheimer Res       Date:  2014-02       Impact factor: 3.498

7.  Prediction of Treatment Response to Donepezil using Automated Hippocampal Subfields Volumes Segmentation in Patients with Mild Alzheimer's Disease.

Authors:  Yoo Hyun Um; Tae-Won Kim; Jong-Hyun Jeong; Ho-Jun Seo; Jin-Hee Han; Seung-Chul Hong; Chang-Uk Lee; Hyun Kook Lim
Journal:  Psychiatry Investig       Date:  2017-09-11       Impact factor: 2.505

8.  Short term response is predictive of long term response to acetylcholinesterase inhibitors in Alzheimer's disease: a starting point to explore Bayesian approximation in clinical practice.

Authors:  Eugenia Rota; Patrizia Ferrero; Rita Ursone; Giuseppe Migliaretti
Journal:  Bioinformation       Date:  2007-08-16

9.  Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer's disease.

Authors:  Yu-Wen Cheng; Ta-Fu Chen; Ting-Wen Cheng; Ya-Mei Lai; Mau-Sun Hua; Ya-Fang Chen; Ming-Jang Chiu
Journal:  Alzheimers Res Ther       Date:  2015-11-23       Impact factor: 6.982

10.  The cholinergic system in subtypes of Alzheimer's disease: an in vivo longitudinal MRI study.

Authors:  Alejandra Machado; Daniel Ferreira; Michel J Grothe; Helga Eyjolfsdottir; Per M Almqvist; Lena Cavallin; Göran Lind; Bengt Linderoth; Åke Seiger; Stefan Teipel; Lars U Wahlberg; Lars-Olof Wahlund; Eric Westman; Maria Eriksdotter
Journal:  Alzheimers Res Ther       Date:  2020-05-06       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.